ClinicalTrials.gg
RecruitingNCT06733922ELIOSUpdated Nov 12, 2026

ELIOS - Investigational Biomarkers to Track Disease Modification in Active RRMS

A Phase 4 interventional study of ETNATM-ProgMS in Relapsing Remitting Multiple Sclerosis (RRMS), sponsored by Novartis Pharmaceuticals. Recruiting at 16 sites in Canada. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Nov 2024; still recruiting 1 year 11 months later.
Updated Nov 12, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
224
Allocation
Not applicable
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 34 studies in Multiple Sclerosis, Relapsing-Remitting by Novartis — 1 open to participants now, 4 under way, none of them phase 3. Multiple Sclerosis, Relapsing-Remitting · Novartis.

Planned enrollment
10th of 26
224 · median 147
Started
2024
with 2 others
Phase 4
15 of 34
1 open now
Registered
31st of 34
by date

Among the 34 studies in Multiple Sclerosis, Relapsing-Remitting by Novartis, this one is the 10th largest by planned enrollment of the 26 interventional ones that give a count, is one of 3 that started in 2024, is one of 15 in phase 4, and was the 31st registered.

Multiple Sclerosis, Relapsing-Remitting

618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.

Browse Multiple Sclerosis, Relapsing-Remitting studies →

Open to participants now

1 of the 34 studies in Multiple Sclerosis, Relapsing-Remitting by Novartis is open now, in 1 country.

By country, each count listing its studies:

Who these studies take

Of the 61 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 44 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Multiple Sclerosis, Relapsing-Remitting by Novartis, or all of them as a file.
02

Study summary

The exploratory ELIOS study aims to assess the value of novel investigational Eye Movement Biomarkers (EMBs) in tracking disease-related changes among a real-world cohort of Canadian patients with active RRMS, within the context of disease-modifying treatment (i.e., ofatumumab). To that end, the study will use the patented investigational, Eye Tracking Neurological Assessment (ETNA-ProgMS) SaMD (v1.0.11 or later), which has not yet received Health Canada approval, to reliably and accurately track eye movements with precision.

03

Conditions studied

  • Relapsing Remitting Multiple Sclerosis (RRMS)

Keywords

  • Ofatumumab
  • Eye Movement Biomarkers (EMB)
  • Patient-Reported Outcomes (PRO)
  • Active Relapsing-Remitting MS (RRMS)
  • Real-World, Neurofilament Light Chain (NfL)
  • Digital, Eye-Tracking
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients eligible for inclusion in the study must fulfill all of the following criteria:

  1. Adult patients who are prescribed ofatumumab as part of routine clinical care as per the PM but who have not yet received their first dose. The decision to prescribe ofatumumab must be made prior to and independent of study participation.
  2. Patients or their legally authorized representatives who sign the Institutional Review Boards/Independent Ethics Committee (IRB/IEC)-approved form.
  3. Patients who meet the EDSS score range of 0 up to 7 at the time of screening and enrollment for ofatumumab treatment.
  4. Patients with a diagnosis of active RRMS according to the 2017 Revised McDonald criteria2.
  5. Patients who can provide blood samples.
  6. Patients who can understand written and spoken Canadian English or French.
  7. Patients who have sufficient corrected visual acuity to allow for accurate reading of the on-screen visual task instructions, in the judgement of the Investigator. If a relapse temporarily affects a patient's corrected visual acuity, the Baseline Visit may be postponed until the patient can accurately read the on-screen visual task instructions, if deemed acceptable by the Investigator and the patient.
  8. Patients with a confirmed diagnosis of MS with no signs of progressive increase in physical disability independent of relapse activity within the past six months, as assessed by a physician.

Exclusion criteria

Exclusion criteria

In order to ensure that the study population will be representative of all eligible patients, no additional exclusions may be applied by the Investigator. Patients meeting any of the following criteria are not eligible for inclusion in this study:

  1. Patients with primary progressive MS, secondary progressive MS without disease activity, clinically isolated syndrome, or radiologically isolated syndrome.
  2. Any disease or condition that could interfere with participation in the study according to the study protocol, or with the ability of the patients to cooperate and comply with the study procedures.
  3. Pregnant or nursing (lactating) women.
  4. Women of , defined as all women physiologically capable of becoming pregnant, unless they are using effective methods of while taking ofatumumab and for six months after stopping medication. Effective contraception methods include:

    • Total abstinence (when this is in line with the preferred and usual lifestyle of the participant). Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception
    • Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy, or tubal ligation at least six weeks prior to enrollment. In case of oophorectomy alone, the reproductive status of the woman must be confirmed by follow-up hormone level assessment
    • Male sterilization at least six months prior to enrollment. For female participants on the study, the vasectomized male partner should be the sole partner for that participant
    • Use of oral (estrogen and progesterone), injected or implanted hormonal methods of contraception, placement of an intrauterine device or intrauterine system, or other forms of hormonal contraception that have comparable efficacy (failure rate \<1%) such as hormone vaginal ring or transdermal hormone contraception
    • Use of barrier methods of contraception (male or female condom, occlusive cap, diaphragm or cervical/vault caps)
    • In case of use of hormonal contraception women participants should have been stable on the same method for a minimum of three months before taking study treatment.
    • If local regulations are more stringent than the contraception methods listed above, local regulations apply and will be described in the ICF.
    • Women are considered if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g., age-appropriate history of vasomotor symptoms). Women participants are considered not of child-bearing potential if they are post-menopausal or have had bilateral tubal ligation, surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy or bilateral salpingectomy at least six weeks prior to first dose of study treatment on study. In the case of oophorectomy alone, a woman is not considered to be of child-bearing potential only when the reproductive status has been confirmed by follow-up hormone level assessment.
  5. Patients with to ofatumumab or to any ingredient in the formulation, active virus, progressive multifocal leukoencephalopathy (PML), severe active infections, in a severely state or with known active .
  6. Patients with an active chronic disease (or stable but treated with immune therapy) of the immune system other than MS (e.g., rheumatoid arthritis, scleroderma, Sjögren's syndrome, Crohn's disease, ulcerative colitis, etc.) or with immunodeficiency syndrome (hereditary immune deficiency, drug-induced immune deficiency).
  7. Patients who are using other drugs within 30 days prior to or at the Baseline Visit, or within a period corresponding to five elimination half-lives, whichever is longer, or who are using other investigational drugs for which the expected pharmacodynamic effect has not returned to baseline.
  8. or inability to undergo regular testing (e.g., MRI, blood tests) as per standard of care.
  9. Patients who have been treated with cladribine or with alemtuzumab at any time within the 12 months prior to the Baseline Visit.
  10. Patients who have had any prior exposure to anti-CD20 B-cell therapy (i.e., ocrelizumab, ofatumumab) or natalizumab.
  11. Medical history or evidence of health issues that, in the opinion of the Investigator, may affect movements and oculomotor control.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
224 participants (estimated)

Study arms

  • Experimental
    ETNATM-ProgMS

    Patients with active RRMS being prescribed ofatumumab as part of routine clinical care will have their eye movements reliably and accurately tracked using ETNATM-ProgMS SaMD (v1.0.11 or later) at baseline, 3-, 6-, 12-, and 24-months following ofatumumab initiation

    Device: ETNATM-ProgMS

Interventions

  • DeviceETNATM-ProgMS

    To that end, the study will use the patented investigational ETNATM-ProgMS SaMD (v1.0.11 or later), which has not yet received Health Canada approval, to reliably and accurately track eye movements with precision. Of note, investigational versions of this SaMD are used for the purpose of clinical research only and will not be commercialized.

06

What researchers measure

Primary outcomes

  1. 1- Change Eye Movement Biomarkers (EMB)

    Change in subtle eye movement anomalies referred to as Eye Movement Biomarkers (EMBs). EMB are derived from composite scores of various Eye Movement metrics. Results stratified by patients experiencing a clinically meaningful change (CMC) in at least one traditional MS outcome (CMCp) or no CMC in all traditional MS outcomes (CMCs/i) at 24 months (or at the time of ofatumumab discontinuation and treated with ofatumumab for at least 12 months)

    Time frame: 6 months from baseline

Secondary outcomes

  1. 1a. Change in EMB

    Change in subtle eye movement anomalies referred to as Eye Movement Biomarkers (EMBs). EMB are derived from composite scores of various Eye Movement metrics

    Time frame: 3,12 and 24 months from Baseline

  2. 1b. Change in EMB trajectories

    Trajectories of investigational EMBs over time

    Time frame: 3-, 6-, 12-, and 24-months

  3. 2a. Change in Annual Relapse Rate (ARR)

    MS relapse is defined as the appearance of a new neurological abnormality or worsening of a previously stable or improving pre-existing neurological abnormality, separated by at least 30 days from onset of a preceding clinical demyelinating event. The abnormality must have been present for at least 24 hours and must have occurred in the absence of fever (\< 37.5°C) or of a known infection.

    Time frame: 12 and 24 months from baseline

  4. 2b. Change in patient disability measured by Expanded Disability Status Scale EDSS

    The EDSS is an ordinal scale used for assessing neurologic impairment in MS based on a neurological examination. It consists of scores in each of seven functional systems (FSs) and an ambulation score that are then combined to determine the EDSS steps (ranging from 0 \[normal\] to 10 (death due to MS). The FSs are Visual, Brain Stem, Pyramidal, Cerebellar, Sensory, Bowel \& Bladder, and Cerebral functions

    Time frame: 3,6,12,24 months from baseline

  5. 2b. Change in patient disability measured by Timed 25-foot walk test (T25-FW)

    The T25- is an objective quantitative test of neurological function. It is an ambulation measurement assessing speed of walking: a timed (in seconds) walk of 25 feet (7.62 meters)

    Time frame: 3,6,12,24 months from baseline

  6. 2b. Change in patient disability measured by the 9-hole peg test (9-HPT)

    The 9- is an objective quantitative test of neurological function. It is measured to assess both right and left arm scores, the metric is the time, in seconds, required to insert and remove nine pegs. The 9-HPT will be administered 4 2 trials per hand, the time for each trial will be averaged with lower times indicating better performance

    Time frame: 3,6,12,24 months from baseline

  7. 2c. Change in objective measures of cognitive impairment as measured by the Symbol Digit Modalities Test (SDMT)

    The SDMT is an objective measure of information processing speed and associated cognitive dysfunction in patients with MS. Using a reference key, the patient has 90 seconds to pair specific numbers with given geometric figures in writing. The raw score corresponds to the total number of correct substitutions, ranging between 0 and 110 with higher scores indicative of better performance.

    Time frame: 3,6,12,24 months from baseline

  8. 2c. Change in objective measures of cognitive impairment as measured by the Brief Visuospatial Memory Test (BVMT-R)

    The BVMT-R is a measure of visuospatial learning, the test consists of six abstract symbols on a sheet of paper. Participants are given ten seconds to study the figures and then try to draw them in the same order on a blank page. Performance is scored on accuracy and location with 0-2 points per symbol for a maximum of 12 points per trial. Patients are asked to repeat the task three times with higher scores indicative of better performance

    Time frame: 3,6,12,24 months from baseline

  9. 2c. Change in objective measures of cognitive impairment as measured by the Rey Auditory Verbal Learning Test (RAVLT)

    The RAVLT is a test of verbal memory that requires the participant to learn and recall a list of 15 words that are orally presented. This test measures learning across five trials, retrieval of the target list after presenting a distracter list and a 30-minute delay, followed by recognition of the target words from among distracter words such as semantic and phonemic foils. The total learning score is the sum of correct answers across the five trials, with higher scores indicative of better performance.

    Time frame: 3,6,12,24 months from baseline

  10. 3a. Association between EMB and annual relapse rate (AAR)

    Association of change in each investigational EMB and ARR established at 12 and 24. To estimate the association of change between each investigational EMB and ARR a Poisson or Negative Binomial Generalized Linear Mixed Model (GLMM) will be used. The metric to assess the association of change over time between each investigational EMB and the outcome variable will be the fixed effect of investigational EMB on ARR, as estimated by the GLMM

    Time frame: 12 and 24 months

  11. 3b. Association of EMBs and objective measures of disability - EDSS, T25-FW, and 9-HPT

    Longitudinal associations of EMBs and objective measures of disability as measured by the EDSS, T25-FW, and 9-HPT. To estimate the longitudinal associations of change between investigational EMBs and measures of disability as measured by EDSS, T25-FW, and 9-HPT scores Linear Mixed Models (LMMs) with a random intercept will be used. The metric to assess the association of change over time between each investigational EMB and the outcome variable will be the population average fixed effect of each investigational EMB on the outcome, as estimated by the corresponding LMM

    Time frame: Up to 24 months

  12. 3c. Association of EMBs and objective measures of cognitive impairment - SDMT

    Longitudinal associations of EMBs and objective measures of cognitive impairment as measured by the SDMT. To estimate the longitudinal associations of change between investigational EMBs and SDMT scores, Poisson GLMMs with a log link and a random intercept will be used. The metric to assess the association of change over time of investigational EMBs and the outcome variables will be the fixed effect of investigational EMBs on the outcomes, as estimated by the GLMMs

    Time frame: Up to 24 months

  13. 3c. Association of EMBs and objective measures of cognitive impairment - BVMT-R, and RAVLT

    Longitudinal associations of EMBs and objective measures of cognitive impairment as measured by the BVMT-R and RAVLT. To estimate the longitudinal associations of change between investigational EMBs and measures of disability as measured by EDSS, T25-FW, and 9-HPT scores Linear Mixed Models (LMMs) with a random intercept will be used. The metric to assess the association of change over time between each investigational EMB and the outcome variable will be the population average fixed effect of each investigational EMB on the outcome, as estimated by the corresponding LMM

    Time frame: Up to 24 months

  14. 4. Change in serum Neurofilament light Chain (sNfL)

    Change in NfL concentration in serum

    Time frame: 3,6,12,24 months from baseline

  15. 5a. Change in patient-reported physical and psychological impact of MS disease as measured by the Multiple Sclerosis impact scale-29 version 2 (MSIS-29v2)

    The MSIS-29v2 is a PRO measure that evaluates the physical and psychological effects of living with MS. The questionnaire consists of 29 items and is scored from 0 to 100, with higher scores indicating a more significant impact of MS. The measure is divided into two subscales: a physical impact scale of 20 items, and a psychological impact scale of 9 items. All items consist of a four-point Likert-type response format: "not at all;" "a little;" "moderately;" and "extremely."

    Time frame: 3,6,12,24 months from baseline

  16. 5b. Baseline assessment and change in patient-reported depression as measured by the Beck depression inventory-II (BDI-II)

    The BDI-II scale is a measure that evaluates depression in patients with MS. It is a self-reported questionnaire that consists of 21 items that measures characteristic attitudes and symptoms of depression. Each item is scored 0 to 3 points for a total score range of 0 to 63. Low scores are associated with low levels of depression, while high scores are associated with high levels of depression

    Time frame: 3,6,12,24 months from baseline

  17. 5c. Change in patient-reported cognitive impairment as measured by the MS neuropsychology questionnaire (MSNQ)

    The MSNQ is a PRO that assesses perceived cognitive impairment among people with MS. It consists of 15 questions that cover different aspects of cognitive function, such as attention, planning, and language. The questions use a scale from 0 (never) to 4 (frequently) to indicate the frequency of cognitive difficulties.

    Time frame: 3,6,12,24 months from baseline

  18. 5d. Change in patient-reported mobility as measured by the MS walking scale-12 version 1 (MSWS-12v1)

    The 12-item MSWS is a PRO measure of the impact of MS on walking ability. The MSWS-12 consists of 12 questions that assess how much MS affects various aspects of walking, such as speed, balance, distance, and effort. The MSWS-12 is scored on a scale from 0 to 100, with higher scores indicating greater impairment

    Time frame: 3,6,12,24 months from baseline

  19. 6. Incidence of treatment emergent adverse events and serious adverse events

    Percentage of participants reporting treatment emergent adverse events and serious adverse events

    Time frame: 24 months

07

Study locations

16 of 16 sites recruiting
  • Novartis Investigative Site
    Calgary, Alberta T2N 4N1, Canada
    Recruiting
  • Novartis Investigative Site
    Calgary, Alberta T3M 1M4, Canada
    Recruiting
  • Novartis Investigative Site
    Edmonton, Alberta T6G 2C8, Canada
    Recruiting
  • Novartis Investigative Site
    Burnaby, British Columbia V5G 2X6, Canada
    Recruiting
  • Novartis Investigative Site
    Vancouver, British Columbia V6T 2A1, Canada
    Recruiting
  • Novartis Investigative Site
    St. John's, Newfoundland and Labrador A1B 3V6, Canada
    Recruiting
  • Novartis Investigative Site
    Halifax, Nova Scotia B3H 3A7, Canada
    Recruiting
  • Novartis Investigative Site
    Halifax, Nova Scotia B3R 1V9, Canada
    Recruiting
  • Novartis Investigative Site
    Ottawa, Ontario K1H 8L6, Canada
    Recruiting
  • Novartis Investigative Site
    Montreal, Quebec H1K 3V9, Canada
    Recruiting
  • Novartis Investigative Site
    Montreal, Quebec H3A 0G4, Canada
    Recruiting
  • Novartis Investigative Site
    Montreal, Quebec H3T 1E2, Canada
    Recruiting
  • Novartis Investigative Site
    Montreal, Quebec H4A 3T2, Canada
    Recruiting
  • Novartis Investigative Site
    Québec, Quebec G1W 4R4, Canada
    Recruiting
  • Novartis Investigative Site
    Sherbrooke, Quebec J1G 2E8, Canada
    Recruiting
  • Novartis Investigative Site
    Regina, Saskatchewan S4V 3A3, Canada
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Mar 2029, 52 months after the start.

Of 28 phase 4 interventional studies under Multiple Sclerosis, Relapsing-Remitting, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 66. This study's planned 52 months is close to that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Nov 2028 → Mar 2029 and completion Nov 2028 → Mar 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2024
First posted
Dec 13, 2024
StartActual
Nov 27, 2024
Primary completionEst.
Mar 31, 2029was Nov 2028
CompletionEst.
Mar 31, 2029was Nov 2028
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added
Show 2 added (2 Canada)
  • Novartis Investigative Site · Montreal, Canada
  • Novartis Investigative Site · Regina, Canada
Nov 12, 2026
Primary completion
Nov 30, 2028→Mar 31, 2029
Nov 12, 2026
Study completion
Nov 30, 2028→Mar 31, 2029
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    2 sites added
    Show 2 added (2 Canada)
    • Novartis Investigative Site · Montreal, Canada
    • Novartis Investigative Site · Regina, Canada
    Primary completion Nov 30, 2028→Mar 31, 2029
    Study completion Nov 30, 2028→Mar 31, 2029
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06733922
Responsible party
Sponsor
First posted
Dec 13, 2024
Start date
Nov 27, 2024
Primary completion
Mar 31, 2029 (estimated)
Completion
Mar 31, 2029 (estimated)
Last update
Nov 12, 2026

Study contacts

Novartis Pharmaceuticals
Contact
novartis.email@novartis.com
+41613241111
Novartis Pharmaceuticals
Contact
Study Director
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion